Actinium Pharmaceuticals, Inc. (ATNM) income statement
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3085% below fair value
$1.08−0.27 (-20.00%)
Close on Nov 18, 2026Market cap $33.96MP/E 3.0Yield –
Actinium Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- 10617.8%
- Net margin
- 12564.4%
- Return on equity, FY2025
- -167.0%
Financial strength
- Current ratio
- 4.08
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 393.9%
Valuation
- P/E ratio
- 3.0
- Price to sales
- –
- Price to book
- 1.12
- Dividend yield
- –
See a number that looks wrong?